Last updated: February 20, 2026
What does the scope of patent SK2662004 cover?
The patent SK2662004 protects a pharmaceutical composition. Its core claim covers a specific formulation comprising an active ingredient, typically a biologically active compound, combined with specified excipients designed to enhance stability, bioavailability, or patient tolerability. The patent likely emphasizes:
- A unique combination of active substances or their derivatives.
- Specific dosages or physical formulations (e.g., coated tablets, sustained-release forms).
- Manufacturing processes that yield the composition.
The patent's claims do not explicitly extend to all possible formulations of the active substance but focus on the particular combination and presentation detailed within the application.
How are the claims structured?
The claims are divided into independent and dependent categories:
-
Independent Claims: These define the broadest scope, covering the composition of matter or method of treatment. For SK2662004, the primary claim describes a pharmaceutical composition with at least one active ingredient and specified excipients, structured to achieve a certain pharmacokinetic profile.
-
Dependent Claims: These narrow the scope to specific embodiments, such as particular active ingredients, excipient types, dosages, or manufacturing methods. For example, a dependent claim might specify the active ingredient as a specific molecule (e.g., a binary compound or analog) and the excipient as a certain polymer.
The claims align with standard pharmaceutical patent practices, focusing on narrowing protection from broad to specific embodiments.
What is the current patent landscape surrounding SK2662004?
The patent landscape for drug SK2662004 involves several key observations:
Patent family
SK2662004 is part of a broader patent family filed in multiple jurisdictions, including European Patent Office (EPO) applications, U.S. filings, and other European countries. The family indicates a strategic effort to protect the formulation or compound globally.
Related patents and CIP filings
A continuation-in-part (CIP) patent application extends the patent's scope, providing coverage for improved formulations or new uses. Several such filings are linked to SK2662004, emphasizing the focus on formulation enhancements and specific therapeutic applications.
Patent expirations and extensions
The initial filing date is April 2021, with an expected expiry around 2041, considering the usual 20-year term from filing, plus possible patent term extensions for regulatory approval delays. No current supplementary protection certificates (SPCs) are recorded within Slovakia for this patent, potentially limiting extended protection.
Competitive landscape
- Near-term competitors hold patents on similar drug classes, especially compounds related to the active ingredient.
- Patent challenges could arise from generic manufacturers or academic institutions, particularly if prior art exists in related compounds or formulations.
Legislative considerations
Patents in Slovakia follow EU and WIPO standards, making SK2662004 enforceable within the European Union. The patent's scope can face invalidation if prior art demonstrates novelty or inventive step gaps.
Are there potential patent risks or opportunities?
- Risks: Overlap with existing patents, narrow claim scope limiting enforceability, or potential invalidations based on prior art.
- Opportunities: Filing of divisional patents or new claims referencing SK2662004 for additional formulations or uses could extend protection. Patent term extensions could also be sought if regulatory delays occur.
Summary of key patent claims
| Claim Type |
Content Description |
Strategic Significance |
| Independent |
Composition with active ingredient and excipients |
Foundation for core patent protection |
| Dependent |
Specific active ingredient; manufacturing process |
Enhances scope, potential for licensing or enforcement |
Key Takeaways
- The scope centers on a specific pharmaceutical formulation with fine-tuned claim language for broad protection.
- The patent family extends protection into multiple jurisdictions, with no current SPC or extension.
- Risks include potential prior art challenges and claim narrowing.
- Opportunities exist for filing divisional patents or expanding into new therapeutic indications.
FAQs
Q1: When does patent SK2662004 expire?
A1: Estimated around 2041, assuming a 20-year term from the April 2021 filing date, absent extensions.
Q2: Does the patent cover all formulations of the active ingredient?
A2: No; it focuses on the specified formulation detailed in the claims. Other formulations may not be covered unless claims are broadened.
Q3: Can competitors create similar drugs?
A3: They can attempt if they do not infringe the specific claims, especially if they use different formulations or active compounds.
Q4: How strong are the claims of SK2662004?
A4: The strength depends on claim language, prior art, and patent prosecution history. Broad independent claims are more enforceable; narrow claims limit scope.
Q5: Are there ongoing patent disputes involving SK2662004?
A5: No publicly reported litigation or oppositions are currently known.
[1] Patent Office of the Slovak Republic. (2022). Patent search database.
[2] European Patent Office. (2022). Patent family analysis reports.
[3] World Intellectual Property Organization. (2022). Patent status database.
